SWP
RIGL icon

ShoreHaven Wealth Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

ShoreHaven Wealth Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10
Closed – – 216
2021
Q1 		$0 Buy
+10
New +$396 ﹤0.01% 295

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

ShoreHaven Wealth Partners's RIGL Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2021, closing a stake of 10 shares.

ShoreHaven Wealth Partners first reported a position in RIGL in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q2 2021.

  • ShoreHaven Wealth Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • ShoreHaven Wealth Partners sold 10 Rigel Pharmaceuticals shares in Q2 2021.
  • ShoreHaven Wealth Partners first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • ShoreHaven Wealth Partners's Rigel Pharmaceuticals position peaked at $0 in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.